Steroid receptors antagonists are used for a variety of clinical purposes including treatment of breast cancer and other hormone- dependent tumors. It has become increasingly apparent that the cellular level of the steroid receptor and the antagonist are not the only factors that determine biological response. Steroid receptor interaction with co-regulatory proteins such as co-activators, co-repressors and other transcription factors are important determinants of the final receptor activity. Because steroid receptor antagonists exhibit varying degrees of hormone agonist activity dependent on cell/tissue type and physiological state of the cell, we hypothesize that the relative agonist/antagonist activity exhibited by these compounds is controlled by the cellular level of expression, or availability, of these other receptors interacting proteins. The overall goal of this research is to identify functionally important receptor-interacting proteins and protein complexes that contribute to steroid antagonists behaving as effective antagonists in some cell/tissue types and physiological states, and as hormone agonists in others. Our research will focus on progesterone receptor (PR) and progesterone antagonists. We expect that many of the fundamental mechanisms discovered with PR will apply to other receptors such as estrogen (ER), androgen (AR) and glucocorticoid receptors (GR).
AIM #1 of the proposal will biochemically isolate and identify functionally important receptor interacting co-activator and co-repressor interacting co-activator and co-repressor complex that correlate with antagonists exhibiting partial agonist activity in different cell types and under different physiological states.
AIM #2 will use a genetic screening strategy to identify other receptor interacting co-regulatory proteins involve din mediating hormone agonist activities of antagonists.
AIM #3 will investigate how steroid antagonists alter receptor interaction with specific co-regulatory proteins to either successfully inactive the receptor or leave it in an active state.
AIM #4 will determine how steroid antagonists influence receptor interaction with other physiologically important gene regulatory proteins. As an example of this mode of regulation, PR co- expression of STAT5 (signal transducers and activators of transcription) mediated activation of milk protein gene expression will be investigated. An understanding of steroid receptor antagonist action at this mechanistic level is anticipated to help in the design of new receptor antagonists (or hormone mimics) that will elicit the desired cell/tissue specific therapeutic response without adverse responses in other tissues.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
2R01DK049030-05
Application #
2758340
Study Section
Biochemical Endocrinology Study Section (BCE)
Program Officer
Margolis, Ronald N
Project Start
1994-09-30
Project End
2002-11-30
Budget Start
1999-02-01
Budget End
1999-11-30
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Pathology
Type
Schools of Medicine
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Elsarraj, Hanan S; Valdez, Kelli E; Hong, Yan et al. (2017) NEMO, a Transcriptional Target of Estrogen and Progesterone, Is Linked to Tumor Suppressor PML in Breast Cancer. Cancer Res 77:3802-3813
Grimm, Sandra L; Hartig, Sean M; Edwards, Dean P (2016) Progesterone Receptor Signaling Mechanisms. J Mol Biol 428:3831-49
TreviƱo, Lindsey S; Bolt, Michael J; Grimm, Sandra L et al. (2016) Differential Regulation of Progesterone Receptor-Mediated Transcription by CDK2 and DNA-PK. Mol Endocrinol 30:158-72
Simons Jr, S Stoney; Edwards, Dean P; Kumar, Raj (2014) Minireview: dynamic structures of nuclear hormone receptors: new promises and challenges. Mol Endocrinol 28:173-82
Moore, Nicole L; Edwards, Dean P; Weigel, Nancy L (2014) Cyclin A2 and its associated kinase activity are required for optimal induction of progesterone receptor target genes in breast cancer cells. J Steroid Biochem Mol Biol 144 Pt B:471-82
Obr, Alison E; Grimm, Sandra L; Bishop, Kathleen A et al. (2013) Progesterone receptor and Stat5 signaling cross talk through RANKL in mammary epithelial cells. Mol Endocrinol 27:1808-24
Obr, Alison E; Edwards, Dean P (2012) The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol Cell Endocrinol 357:4-17
Garza, Anna S; Khan, Shagufta H; Moure, Carmen M et al. (2011) Binding-folding induced regulation of AF1 transactivation domain of the glucocorticoid receptor by a cofactor that binds to its DNA binding domain. PLoS One 6:e25875
Wardell, Suzanne E; Narayanan, Ramesh; Weigel, Nancy L et al. (2010) Partial agonist activity of the progesterone receptor antagonist RU486 mediated by an amino-terminal domain coactivator and phosphorylation of serine400. Mol Endocrinol 24:335-45
Holley, Aaron K; Kiningham, Kelley K; Spitz, Douglas R et al. (2009) Progestin stimulation of manganese superoxide dismutase and invasive properties in T47D human breast cancer cells. J Steroid Biochem Mol Biol 117:23-30

Showing the most recent 10 out of 28 publications